Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0D9LB
|
||||
| Former ID |
DCL000316
|
||||
| Drug Name |
BIBV 308
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Peripheral vascular disease [ICD9: 443.9; ICD10:I73.9] | Phase 1 | [1] | ||
| Company |
Boehringer Ingelheim
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C23H27N5O2
|
||||
| Canonical SMILES |
CC(C)(C)N=C(NC#N)NC1=CC=CC(=C1)C(=CCCCC(=O)O)C2=CN=CC=C<br />2
|
||||
| InChI |
1S/C23H27N5O2/c1-23(2,3)28-22(26-16-24)27-19-10-6-8-17(14-19)20(11-4-5-12-21(29)30)18-9-7-13-25-15-18/h6-11,13-15H,4-5,12H2,1-3H3,(H,29,30)(H2,26,27,28)/b20-11+
|
||||
| InChIKey |
XUTLOCQNGLJNSA-RGVLZGJSSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Thromboxane A2 receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Platelet activation | |||||
| Reactome | Prostanoid ligand receptors | ||||
| G alpha (q) signalling events | |||||
| G alpha (12/13) signalling events | |||||
| Thromboxane signalling through TP receptor | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Small Ligand GPCRs | |||||
| Signal amplification | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02223013) Relative Bioavailability and Tolerability of Two New Different Extended Release Capsules of BIBV 308 SE, Versus a Solution of BIBV 308 SE in Healthy Subjects. U.S. National Institutes of Health. | ||||
| REF 2 | AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II. Kidney Int Suppl. 2005 Jan;(93):S3-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.